Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

10.13USD
14 Dec 2017
Change (% chg)

$-0.31 (-2.97%)
Prev Close
$10.44
Open
$10.42
Day's High
$10.58
Day's Low
$10.11
Volume
211,911
Avg. Vol
242,151
52-wk High
$17.96
52-wk Low
$8.10

Select another date:

Tue, Dec 5 2017

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211

* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

BRIEF-Lexicon Pharma reports positive pooled continuous glucose monitoring data

* Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin

BRIEF-Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin

* Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

BRIEF-Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo

* Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo® (telotristat ethyl) Source text for Eikon: Further company coverage:

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

Select another date: